Sign in Subscribe

Topic

CPIC

A collection of 130 issues

ClinGen Pharmacogenomics Working Group (PGxWG) Follow-Up Survey

The ClinGen Pharmacogenomics Working Group (PGxWG) has just launched a second survey to solicit feedback about the criteria and terminology that should be used to define clinical validity and actionability for pharmacogenes and variants from both the PGx community and the wider genetics and medical communities. Please note that this

ClinGen Pharmacogenomics Working Group (PGxWG) Survey

The ClinGen Pharmacogenomics Working Group (PGxWG) has launched a survey to solicit feedback about the criteria and terminology that should be used to define clinical validity and actionability for pharmacogenes and variants. The ClinGen PGxWG is a multi-disciplinary team of researchers and professionals with expertise in pharmacogenomics (PGx), clinical pharmacology,

Response to the American Academy of Pediatrics' Statement "Eliminating Race-Based Medicine"

On May 2nd, the American Academy of Pediatrics (AAP) released a pre-published policy statement titled “Eliminating Race-Based Medicine,” noting that race is a “historically derived social construct that has no place as a biologic proxy.” The statement provides necessary and meaningful commentary on “the medical field’s history of inaccurate

National Academy Seeking Public Feedback on Use of Population Descriptors in Genomics Research

The National Academy's Committee on Use of Race, Ethnicity, and Ancestry as Population Descriptors in Genomics Research is now actively requesting public comments from those involved in genomics research about how they use descriptors like race, ethnicity, and ancestry as well as thoughts on potential improvements to usage.

Update to individual statin pathways to support release of new CPIC guidelines for statins

To coincide with the release of the updated CPIC guidelines for SLCO1B1, ABCG2 and CYP2C9 and statin-associated musculoskeletal symptoms, we have updated the statin pharmacokinetic (PK) pathways. We now have one PK pathway for each individual drug in the guideline and have added details of the specific metabolites as well

CPIC Publishes Guideline for SLCO1B1, ABCG2, CYP2C9 and Statin Therapy

The CPIC guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (SAMS) has been published in the journal Clinical Pharmacology and Therapeutics. This guideline is an update to the CPIC guideline for simvastatin and SLCO1B1, but now includes expanded literature review on four additional genes, ABCG2, CYP2C9, HMGCR and

Registration opens for CPIC-PGRN 2022 meeting in Denver, Colorado

We are excited to announce that registration is open for the 2022 CPIC-PGRN meeting: Diversifying PGx Science to Improve Implementation. The meeting will be held at the University of Colorado on May 10th, 11th, and 12th in Denver, CO. Registration, agenda, and hotel information available at the meeting website. Early

CPIC Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update

The 2022 CPIC Guideline update for CYP2C19 Genotype and Clopidogrel Therapy is now published in Clinical Pharmacology and Therapeutics. The article can be accessed on the PharmGKB page for clopidogrel and on the CPIC website. Clopidogrel is a commonly prescribed antiplatelet prodrug and CYP2C19 is a significant contributor in the

Please help secure funding for PGx!!

The ability to predict ahead of time which drugs will be effective for a unique patient and determine which medications may cause patients serious issues, will save lives, improve health care outcomes, and decrease health care costs. Several genes in the human genome play a role in how people respond

CPIC® Guideline for Potent Volatile Anesthetic Agents and Succinylcholine and RYR1 and CACNA1S update

The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel recently published recommendations for RYR1 pathogenicity classifications in malignant hyperthermia susceptibility (PMID: 33767344). These revised ACMG/AMP criteria were applied to the 44 variants originally included in the CPIC recommendations (PMID: 30499100) and 29 variants were classified as pathogenic, 13 as